|
2020CSCO丨郭军教授：中国黑色素瘤科研初具蓝图，将来需多中心协同推进
盘点2020｜斯璐：黑色素瘤治疗发展盘点
解码黑色素瘤青年探索者斯璐：她亦曾想过放弃
积石成山丨中国黑色素瘤表率性论著周期总结
历史回顾丨中国临床肿瘤学年度科研发展2015-2021黑色素瘤部分要紧发展+值得关注的发展回顾
● 中国原创黑色素瘤 ●
●●●Original melanoma of China●●●
J Clin Oncol（3篇），Ann Oncol（2篇），Clin Cancer Res（3篇），J Immunother Cancer（2篇），Eur J Cancer（4篇）
中国原创黑色素瘤
Chin J Cancer Res
Chin J Cancer ResA phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）
Eur J Cancer
Eur J Cancer A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients（2011）
J Clin Oncol
J Clin Oncol Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification（2011）
Mol Ther
Mol TherA phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma（2012）
Clin Cancer Res（ChiCTR-TRC-11001798）
Clin Cancer Res Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma（2013）
Ann Oncol（NCT01028222）
Ann Oncol Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial（2017）
BMC Cancer（NCT01910181）
BMC CancerVemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study（2018）
Transl Oncol（KEYNOTE 151）
Transl Oncol A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma（KEYNOTE-151）（2019）
J Clin Oncol（NCT03086174）
J Clin Oncol Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial（2019）
Eur J Cancer（NCT02083354）
Eur J CancerOpen-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma（2020）
Clin Cancer Res（NCT03013101）
Clin Cancer ResSafety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial（2020）
J Immunother Cancer（CTR20160872）
J Immunother Cancer Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）
J Clin Oncol（NCT02023710）
J Clin Oncol Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma（2021）
J Immunother Cancer（NCT03086174）
J Immunother Cancer Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis（2021）
Front Oncol（NCT02083354）
Front Oncol Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneousmelanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial（2021）
Eur J Cancer（NCT03454919）
Eur J Cancer Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway（2021）
Melanoma Res（NCT03422445）
Melanoma Res Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy（2022）
J Immunother Cancer（CTR20140631 and CTR20150881）
J Immunother Cancer OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study（2022）
Ann Oncol（NCT03178123）
Ann Oncol Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial（2022）
BMC Cancer（NCT02738489）
BMC Cancer Safety, activity and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study（2022）
Clin Cancer Res（NCT04091217）
Clin Cancer ResAtezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study（2022）
Eur J Cancer（NCT03932253）
Eur J Cancer A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma（2022）
Front Oncol（KEYNOTE 151）
Front Oncol Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study（2022）
整理者
| 
发表于 2024-5-17 12:49:57
发表于 2024-5-17 13:07:46